Taiji Tsukamoto
Overview
Explore the profile of Taiji Tsukamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
347
Citations
2749
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishida S, Nagaishi K, Motoya M, Kumagai A, Terada N, Kasuga A, et al.
PLoS One
. 2021 Jun;
16(6):e0253646.
PMID: 34166439
Purpose: Since December 2019, coronavirus disease 2019 (COVID-19) has spread rapidly across the world. During the pandemic, physicians in our hospital have had to respond both to the issue of...
2.
Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Nishimura K, et al.
Cancer Med
. 2021 May;
10(10):3240-3248.
PMID: 33932114
Background: We evaluated patient-reported outcomes (PRO) during neoadjuvant androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) followed by either adjuvant continuous ADT (CADT) or intermittent ADT (IADT) for...
3.
Kitamura H, Hinotsu S, Tsukamoto T, Shibata T, Mizusawa J, Kobayashi T, et al.
Jpn J Clin Oncol
. 2020 Jul;
50(12):1464-1469.
PMID: 32699909
Background: Although neoadjuvant chemotherapy provides survival benefits in muscle-invasive bladder cancer, the impact of neoadjuvant chemotherapy on health-related quality of life has not been investigated by a randomized trial. The...
4.
Ito K, Kobayashi M, Komiyama M, Naito S, Nishimura K, Yonese J, et al.
Cancer
. 2020 Jun;
126(17):3961-3971.
PMID: 32573779
Background: To date, research has not determined the optimal procedure for adjuvant androgen deprivation therapy (ADT) in patients with locally advanced prostate cancer (PCa) treated for 6 months with neoadjuvant...
5.
6.
Onozawa M, Akaza H, Hinotsu S, Oya M, Ogawa O, Kitamura T, et al.
Cancer Med
. 2018 Aug;
7(10):4893-4902.
PMID: 30151999
Background: This study investigated how differences in the method of the first-line androgen deprivation therapy (ADT) affected the time to castration-resistant prostate cancer. Methods: The Japan Study Group of Prostate...
7.
Tanaka T, Itoh N, Sasao T, Maeda T, Tsukamoto T, Kamiya H
Reprod Med Biol
. 2018 Apr;
5(3):211-214.
PMID: 29662399
We reviewed the findings of scrotal exploration, histological examination and clinical parameters in patients with clinically suspected idiopathic or inflammatory obstructive azoospermia without confirmation by isolated testis biopsy in advance....
8.
Ozono S, Tsukamoto T, Naito S, Horie S, Ohashi Y, Uemura H, et al.
Cancer Sci
. 2018 Apr;
109(6):1920-1929.
PMID: 29624800
Non-inferiority in the cumulative castration rate of the 3-month formulation of degarelix compared with the 3-month formulation of goserelin was evaluated in subjects with prostate cancer. A phase III, open-label,...
9.
Ozono S, Tsukamoto T, Naito S, Ohashi Y, Ueda T, Nishiyama T, et al.
Jpn J Clin Oncol
. 2017 Mar;
47(5):438-446.
PMID: 28334771
Objective: To evaluate the efficacy and safety of degarelix 3-month depot in Japanese patients with prostate cancer. Methods: In this Phase II, open-label, parallel-group study, 155 Japanese prostate cancer patients...
10.
Akaza H, Hirao Y, Kim C, Oya M, Ozono S, Ye D, et al.
Prostate Int
. 2016 Oct;
4(3):88-96.
PMID: 27689065
The Asian Prostate Cancer (A-CaP) Study is an Asia-wide initiative that has been developed over the course of 2 years. The A-CaP Study is scheduled to begin in 2016, when...